RETA is a synthetic peptide known as a triple-receptor agonist, designed to target the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. In laboratory research, it is utilized to investigate the coordinated regulation of glucose homeostasis, lipid metabolism, and energy expenditure through simultaneous multi-pathway signaling. For research use only.
RETA is a specialized research reagent engineered for the study of advanced metabolic intervention. As a triple-agonist, it provides a unique model for investigating the intersection of GLP-1 and GIP incretin effects with the thermogenic properties of glucagon signaling. In research settings, it is valued for its potential to address multiple pathways of metabolic dysfunction simultaneously. Researchers use this peptide to observe transitions in metabolic flexibility and changes in adipose tissue utilization in various mammalian models. Supplied as a stable, lyophilized powder, it is intended strictly for laboratory research and is not for human or veterinary administration.
